Cold air can irritate the airways that carry air into the lungs, potentially causing symptoms like coughing, chest tightness, and trouble breathing.

Delhi's air quality has plunged to 'severe plus', posing grave health risks. Experts warn that even healthy individuals can ...

The 2025 AAO‐HNSF adult sinusitis guideline, an update of the 2015 guideline, offers evidence-based recommendations on rhinosinusitis management.

Christmas Tree Syndrome can trigger sneezing, sniffles, coughing, and itchy eyes during the holidays. Doctors say real trees release mold spores, dust, and plant resins, while stored artificial trees ...

In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

Please provide your email address to receive an email when new articles are posted on . The annualized exacerbation rate was 3.18 per patient-year before tezepelumab and 1.97 per patient-year after ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

TUESDAY, Aug. 12, 2025 (HealthDay News) -- Inflammatory pathways that contribute to asthma exacerbations have been identified in children with eosinophilic asthma receiving mepolizumab, according to a ...

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...